Coming Soon!
This case conference presents Mr. A, a male in his 30s with treatment-resistant schizophrenia, a history of methamphetamine use, and multiple traumatic brain injuries. His antipsychotic trials included aripiprazole LAI, which was ineffective, followed by the addition of clozapine. Through this case, participants will explore traditional concepts of treatment resistance and pseudo-resistance, the roles of confounders and mediators in antipsychotic response, and how biological heterogeneity, illness chronicity, and psychosocial factors shape outcomes. The discussion will also cover when LAIs and adjunctive mood stabilizers may improve treatment, compare high-dose olanzapine and clozapine in inadequate responders (including partial response versus nonresponse to D2 antagonism), and highlight the benefits of measurement-based treatment.